Vantage Point: Hepatitis C

Share this article:
Jeff Glor
Jeff Glor

Think of any severely underserved therapeutic area today. What if:

• Efficacy rates around 40% at least doubled;

• Toxicities that crush adherence and prevent many from starting treatment fell drastically;

• The long treatment course decreased to one-fourth its duration;

• And we eliminated the need for injectable therapy?

Either you're thinking it's time to wake up, or you've guessed the area where this metamorphosis is happening: hepatitis C virus.

It started in 2011 with approval of Vertex's Incivek and Merck's Victrelis. The next wave of agents from Gilead, Abbott, BMS, Janssen and others will offer shorter therapy, utility across difficult-to-treat patients, even higher SVR and, the Holy Grail, elimination of injectable, tolerability-busting interferon.

This revolution could take place in less than a five-year stretch.

Who wins? Patients, but the dividends go beyond that. HCPs could see a huge decrease in hours logged toward patient education and side-effect support. Practices that cap the number of patients they treat may be able to significantly increase capacity.  Long-term costs could shrink dramatically.

Much of what's published about the pharma industry has negative connotations.  “Pharma bashing” is popular, with constant talk about how our R&D model is broken, our sales/marketing efforts are obsolete, etc. Fair enough—let's revamp.

But let's celebrate when amazing success stories happen.  The revolution in HCV is a great success. As it became evident that a large HCV+ cohort would likely need medical intervention, pharma responded. And the results could not be more stunning.

Jeff Glor is executive director, BioVid.
Share this article:
close

Next Article in Vantage Point

Email Newsletters

More in Vantage Point

Vantage Point: Payers—the "experts" in healthcare research

Vantage Point: Payers—the "experts" in healthcare research

Access to payers is about knowledge, about understanding what they do in their jobs

Vantage Point: Determining "fair market value"

Vantage Point: Determining "fair market value"

Should pharma formulate a super matrix to determine the FMV of research incentives?

Vantage Point: Marketing Support for Clinical Trials

Vantage Point: Marketing Support for Clinical Trials

Pharmaceutical companies must provide robust marketing support for their clinical trials